• Skip to primary navigation
  • Skip to main content
Diagnostic Detectives Network logo

Diagnostic Detectives Network

Precision Medicine for Every Patient

  • LEARN
    Expert Centers
    • Wisdom
    • Women’s Health
    • Public Health
    • Brain
      • Brain tumors
      • Brain Aneurysms AVM BDAVF
      • ADHD and Autism
      • Multiple Sclerosis
    • Spine
    • Heart
      • Coronary Artery Disease
      • Heart Valve Problems
      • Other Heart Diseases
      • Pulmonary Hypertension
    • Breast Cancer
    • Colorectal Cancer
      • Peritoneal Cancer
    • Lung Cancer
    • Prostate Cancer
    • Integrative Medicine
    • Hematology
    • Coronavirus
    • Liver-Pancreas-Esophagus-Gallbladder
  • BENEFIT
    Our Services
  • CONNECT
    Contact
  • About
    • Our Mission | Our Story
    • Expert Advisory Board
    • Testimonials from experts
  • How It Works
  • Show Search
Hide Search
Home » Breast Cancer » Precision medicine in breast cancer therapy. Targeted drugs 
or chemotherapy? 2

Precision medicine in breast cancer therapy. Targeted drugs 
or chemotherapy? 2



Video transcript

A new diagnosis of breast cancer presents the patient with serious clinical decisions to make. An early-stage breast cancer treatment in the precision medicine era, as you mentioned, evolves all the time. New targeted therapies for early-stage breast cancer treatment go through many clinical trials. What is new in customizing the cancer treatment for patients with early breast cancer?

I believe the most important data with immune checkpoint inhibitors. Recently, we had the opportunity to listen to the data of KEYNOTE-522. That is a prospective randomized clinical trial. It evaluated the role of pembrolizumab in the early triple-negative breast cancer. The addition of pembrolizumab to standard chemotherapy improved the rate of pathological complete response. But most importantly, pembrolizumab improved the rate of invasive disease-free survival, with the trend in positivity in overall survival. So using immune checkpoint inhibitors, both in the neoadjuvant and in the adjuvant setting for early triple-negative breast cancer, may potentially improve overall survival in this patient population.

In what situations patients with early breast cancer might avoid chemotherapy altogether? Is there such a chemotherapy-free breast cancer treatment scenario available now? Will it be available shortly? For some patients?

This is a very good question. We have several genomic tests actually, like Recurrence Score or like Mammaprint. They can really select those patients who can avoid chemotherapy. Let us specifically go into the details. You may be a postmenopausal woman with estrogen receptor-positive and HER2/neu-negative breast cancer. You perform a test Oncotype DX Recurrence Score test. If you have an intermediate risk score or a low-risk score, you can for sure avoid chemotherapy even if you have cancer involvement in one to three lymph nodes. So this is a large population of breast cancer patients who, in the early breast cancer setting, can really avoid chemotherapy.

Is there anybody in the pre-menopausal women patients who might avoid the chemotherapy altogether?

This is a very good question. For premenopausal patients with breast cancer, we don’t have exactly the same results of the postmenopausal breast cancer setting. But I am quite sure that some breast cancer patients with low recurrence scores may for sure avoid chemotherapy. They can receive endocrine therapy alone for breast cancer.

There is more and more use of extensive genomic sequencing. For example, Tempus xT panel, Foundation Medicine panels are available. How often do you recommend to your patients to have more extensive genetic testing in the setting of a new breast cancer diagnosis?

In the context of metastatic metastatic breast cancer, the use of those genomic panels should be reserved for patients who are candidates to participate in clinical trials. So, in my opinion, in a comprehensive cancer center like mine, the European Institute of Oncology of Milano, we should offer NGS for all metastatic breast cancer patients who are potential candidates for clinical trials.

Expert Center: Breast Cancer, Women's HealthTopic: Chemotherapy, Dr. Giuseppe Curigliano, Precision Medicine, Targeted cancer therapy

See our services
How it works

Leading doctors discuss how not to make a mistake when choosing treatment:


Explore more

LEARN

Expert Centers

Wisdom
COVID-19
Brain
Heart
Lung cancer
Colon cancer
Prostate cancer
Hematology
Women's Health
Integrative Medicine
Precision Medicine
Public Health


BENEFIT

About us

Our services
How it works

Advisory Board
Expert Testimonials

CONNECT

Contact us

WhatsApp
Telegram
E-mail

GLOBAL

English

Chinese
Dutch
German
French
Hebrew
Japanese
Korean
Portuguese
Russian
Spanish

Footer

© 2022 · Diagnostic Detectives Network · Privacy · Terms